CN102274433A - Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof - Google Patents
Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof Download PDFInfo
- Publication number
- CN102274433A CN102274433A CN 201110226694 CN201110226694A CN102274433A CN 102274433 A CN102274433 A CN 102274433A CN 201110226694 CN201110226694 CN 201110226694 CN 201110226694 A CN201110226694 A CN 201110226694A CN 102274433 A CN102274433 A CN 102274433A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- rhizoma
- inflammatory disease
- pelvic inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicine for treating chronic pelvic inflammatory disease, which is an oral liquid prepared from the following Chinese medicinal herbs in parts by weight: 220-260 parts of taraxacum, 220-260 parts of glabrous greenbrier rhizome, 100-140 parts of red paeonia, 140-180 parts of kuh-seng, 140-180 parts of radix salviae miltiorrhizae, 140-180 parts of cymose buckwheat rhizome, 100-140 parts of rhizoma cyperi and 100-140 parts of radix achyranthis bidentatae. The pharmacodynamical experiment indicates that the traditional Chinese medicine has obvious curative effect on chronic pelvic inflammatory disease caused by moist heat stagnation.
Description
One, technical field
The present invention relates to a kind of compound Chinese patent medicine, exactly is a kind of Chinese medicine for the treatment of chronic pelvic inflammatory disease.
Two, background technology
Chronic pelvic inflammatory disease is a kind of commonly encountered diseases, the frequently-occurring disease of gynecological, also is difficult disease.Modern medicine is thought, connective tissue and pelvic peritoneum generation chronic inflammatory disease around female sex organs reach are relevant with the factors such as kind, virulence and body defensive enginery of invading pathogen.Main pathogenic bacterium are followed successively by escherichia coli, staphylococcus, Jia Xingrongxuexinglianqiujun, Bacteroides, enterococcus and gonorrhea diplococcus, tubercule bacillus, anaerobism Pseudomonas etc.The a lot of diseases of chronic pelvic inflammatory disease are in utero postoperative infection, puerperium, post-abortion or menstruation infection, and pathogen is invaded and endometrium, fallopian tube, ovary and abdominopelvic cavity along mucosa is up by cervix uteri; Also can be from lymph diffusion or pelvic cavity phlebothrombosis.If acute stage the state of an illness fail to be controlled effectively, often change chronic persistence over to.Cause the congested swelling of fallopian tube, inflammatory exudation, even suppurate formation pyosalpinx or tubo-ovarian abscess; Also can involve pelvic cavity, between rear, uterus broad ligament and rectum, form soft, the indefinite border enclosed mass of matter.Primary disease sickness rate height influences WomanHealth, easily outbreak repeatedly.The life-time service antibiotic causes antibacterial to produce certain drug resistance, affects the treatment.As escalated dose or prolongation administration time, not only unhelpful to treating, cause severe complications such as dysbacteriosis on the contrary easily.Thereby, inquire into new research approach and Therapeutic Method as clinical treatment targetedly, be still the current problem to be solved that has.
The record of this name of disease is not arranged in the Chinese medicine, according to its clinical manifestation can sporadically appear in TCM Gynecology that it " leaks down ", in the disease kinds such as " dysmenorrhea ", " leukorrhagia ", " married woman's stomachache ", " heating ", " mass in the abdomen ".The primary disease endogenous cause of ill is many is detained, blocks mechanism of qi so that caused by energy stagnation and blood stasis by emotion pent-up, incoordination between the liver and spleen, retention of damp-heat in the interior, blood stasis.Acute stage, show as the excess syndrome pattern of syndrome that damp and hot heap soil or fertilizer over and around the roots is contained, if delay or malpractice then change chronic pelvic inflammatory disease into, shows as the interlacing syndrome feature of damp and hot congestion.At this moment, if the simple method that adopts heat-clearing and toxic substances removing, or adopt the antibiotics treatment all to be difficult to obtain satisfied curative effect merely.The pure Chinese medicinal preparation that is used for the treatment of chronic pelvic inflammatory disease on the market lays particular emphasis on heat-clearing and toxic substances removing, dampness removing or blood circulation promoting and blood stasis dispelling, eliminating stagnation mostly, and in a certain respect, though effective in cure, the course of treatment is long.
Three, summary of the invention
The present invention aims to provide a kind of Chinese medicine for the treatment of chronic pelvic inflammatory disease, and technical problem to be solved is to integrate heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, damp eliminating eliminating stagnation, by invigorate blood circulation, the ruling by law of eliminating stagnation, collateral dredging treats chronic pelvic inflammatory disease.
The Chinese medicine of the treatment chronic pelvic inflammatory disease that the present invention is alleged is the oral formulations that is obtained by following parts by weight of Chinese traditional medicine material compositions processing:
Preferably:
In above-mentioned composition, also be added with Rhizoma Curcumae 60-100 part, Rhizoma Corydalis 60-100 part; 80 parts of preferred Rhizoma Curcumae, 80 parts of Rhizoma Corydalis.
More than ten flavor Chinese crude drugs should meet " pertinent regulations that wait item about " Herba Taraxaci ", " Rhizoma Smilacis Glabrae " of Chinese pharmacopoeia version in 2010.
This compositions is by Chinese medicine monarch, minister, the principle compatibility helping, make, and wherein Herba Taraxaci is monarch, and Rhizoma Smilacis Glabrae, Radix Paeoniae Rubra are minister, and Radix Sophorae Flavescentis, Radix Salviae Miltiorrhizae, Rhizoma Fagopyri Dibotryis, Rhizoma Cyperi, Rhizoma Curcumae, Rhizoma Corydalis are assistant, the Radix Achyranthis Bidentatae assistant, makes furthermore.
Described processing is meant preparation extract earlier, and post-treatment gets oral formulations, and described extract is:
1, Radix Paeoniae Rubra, Radix Sophorae Flavescentis, Radix Salviae Miltiorrhizae are the extract that ethanol extraction obtains.
2, Rhizoma Smilacis Glabrae, Herba Taraxaci, Rhizoma Fagopyri Dibotryis, Rhizoma Curcumae, Rhizoma Cyperi, Radix Achyranthis Bidentatae and above-mentioned medicinal residues are the extract that water extract-alcohol precipitation obtains.
3, Rhizoma Corydalis is the plant tuber position, and starch-containing amount height is directly pulverized and is used as medicine.
This preparation method of Chinese medicine is as follows:
1, Radix Paeoniae Rubra, Radix Sophorae Flavescentis, the Radix Salviae Miltiorrhizae of getting proportional quantity mixes, and the concentration that adds at least 5 times of amounts is 75-85% (percent by volume, down together) alcohol reflux at least twice, is no less than 1 hour at every turn, and isolated by filtration obtains filtrate and adds filtering residue.Merging filtrate, concentrating under reduced pressure reclaims ethanol, and the thick paste I that is concentrated into relative density 1.25-1.40 (80 ℃) is standby.
2, above-mentioned filtering residue mixes with Rhizoma Smilacis Glabrae, Herba Taraxaci, Rhizoma Fagopyri Dibotryis, Rhizoma Curcumae, Rhizoma Cyperi, the Radix Achyranthis Bidentatae of proportional quantity, add the water reflux, extract, of at least 8 times of amounts or decoct at least twice, be no less than 1 hour at every turn, should keep the decocting liquid liquid level relatively stable during decoction, isolated by filtration obtains filtrate and filtering residue.
3, the filtrate that obtains of combining step 2, be evaporated to the clear paste of relative density 1.05-1.20 (80 ℃), add ethanol, make determining alcohol 55-65%, leave standstill after fully stirring, separate to precipitating complete after-filtration, filtrate decompression concentrates and reclaims ethanol, is concentrated into the thick paste II for future of relative density 1.25-1.40 (80 ℃).
4, merge thick paste I and thick paste II and mix with the Rhizoma Corydalis fine powder and to be aided with the adjuvant that pharmaceutically allows and to process oral formulations with known method.
Described oral formulations is selected from capsule, granule, ordinary tablet or slow releasing tablet etc.Preferred capsule.
The taking dose of this Chinese medicine: adult's oral dose is amounted to crude drug 15-18g, day clothes three times, each 5-6g.
This Chinese medicine collected explanations or commentaries poison, damp eliminating, invigorate blood circulation in one, evident in efficacy to the chronic pelvic inflammatory disease due to the dampness and heat stasis.
Four, the specific embodiment
(1) be example with the processing capsule, non-limiting examples is described below:
Get Herba Taraxaci 240g, Rhizoma Smilacis Glabrae 240g, Radix Sophorae Flavescentis 160g, Radix Salviae Miltiorrhizae 160g, Rhizoma Fagopyri Dibotryis 160g, Radix Paeoniae Rubra 120g, Rhizoma Cyperi 120g, Radix Achyranthis Bidentatae 120g, Rhizoma Curcumae 80g, Rhizoma Corydalis 80g prescription.
1, the Radix Paeoniae Rubra, Radix Sophorae Flavescentis, Radix Salviae Miltiorrhizae of getting proportional quantity is with 80% alcohol reflux 3 times, and each 1.5 hours, alcohol adding amount was 8 times of amounts, filter, and merge extractive liquid,, filtrate recycling ethanol also is evaporated to the thick paste I of relative density 1.30-1.35 (80 ℃), and is standby.
2, Rhizoma Smilacis Glabrae, Herba Taraxaci, Rhizoma Fagopyri Dibotryis, Rhizoma Curcumae, Rhizoma Cyperi, the Radix Achyranthis Bidentatae with above-mentioned filtering residue and proportional quantity adds 12 times of medical material water gagings decoctions 3 times, each 1.5 hours, collecting decoction filters, and filtrate decompression is concentrated into the clear paste of relative density 1.10-1.15 (80 ℃), adding ethanol makes determining alcohol reach 60%, fully stir, static 24 hours, filter, decompression filtrate recycling ethanol also is concentrated into the thick paste II of relative density 1.30-1.35 (80 ℃), and is standby.
3, thick paste I and thick paste II are merged, further drying under reduced pressure (80 ℃) is ground into fine powder, in 1000 " 0 " number capsules of packing into behind the Rhizoma Corydalis fine powder mix homogeneously of adding proportional quantity.
(2) pharmacodynamic experiment result
Test material
Laboratory animal: wistar rat, body weight 170-230g female (each experimental animal body weight difference be no more than 50g), the quality certification number: SCXK-(Ji) 2003-0004; Kunming kind white mice, body weight 18-22g, female, the quality certification number: SCXK-(Ji) 2003-0004.All rats, white mice are all available from high-new medical experiment zooscopy center, Changchun.
Trial drug: this Chinese medicinal capsule.Specification: the 0.4g/ grain is made into desired concn for gastric infusion with distilled water during experiment.Adrenalin hydrochloride (Adr) injection is produced by Tian Feng pharmaceutical factory, Shanghai, lot number: 940501; Chloral hydrate, Gaobeidian City, Hebei spring scenery chemical reagent work produces, lot number: 960908.
Instrument: the experimental thrombus in vivo of BT87-3 type forms analyzer, is supervised by medical college cardiovascular research chamber, packet header; 752 type ultraviolet spectrophotometers are produced by Shanghai the 3rd analytical tool factory.
Test method and result
1, antiinflammatory action:
1.1, the influence of rat paw edema due to the on Carrageenan:
Get 50 of rats, be divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 0.70g/kg dosed administration group; This Chinese medicinal capsule 0.70,0.35, three dosed administration groups of 0.18g/kg.Be administered once every day, successive administration 5 days.Injected 1% carrageenin 0.1ml/ down only in the right back toes aponeurosis (aponeuroses) of rat in 1 hour after the last administration.And in injecting the rat paw edema degree of surveying respectively in back 1,2,3,4,5,6,24 hour.With two back foot swelling differences as the swelling index.The results are shown in Table 1.
By table 1 result as seen, the rat paw edema that KANGFUYAN JIAONANG and this Chinese medicinal capsule on Carrageenan cause has the obvious suppression effect, and presents certain dose-effect relationship, and sustainable 24 hours of this Chinese medicinal capsule 0.70g/kg effect.
1.2, to the influence of rat uterus inflammation
Get 50 of healthy rats, after the lumbar injection pentobarbital sodium 30mg/kg anesthesia, inject 0.1ml paste (liquefied phenol 3ml for uterus, every Mus left side, adding distil water is to 10ml, add an amount of chemical paste again), make inflammatory model, wound gives penicillin (directly be coated with and spread), is divided into 5 groups subsequently at random.The blank group; KANGFUYAN JIAONANG 0.70g/kg dosed administration group; This Chinese medicinal capsule 0.70,0.35, three dosed administration groups of 0.18g/kg.Be administered once every day, successive administration 12 days.After the last administration 1 hour, kill animals was taken out the bilateral uterus and is weighed, and deducted the right side uterus weight with the left side uterus weight of every Mus and was inflammation swelling degree, the results are shown in Table 2.
By table 2 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule 0.70,0.35g/kg have the obvious suppression effect to the swelling degree of inflammation of uterus, and present certain dose-effect relationship.
1.3, to the bullate influence of rat granuloma:
With 50 of healthy rats, lumbar injection pentobarbital sodium 30mg/kg anesthesia, cut the long osculum of 1cm at groin place, the left and right sides of every Mus, autoclaving cotton balls (penicillin and streptomycin mixed liquor 0.2ml immersion with 20mg, 60 ℃ of oven dry) implant from incision subcutaneous, about each skin suture immediately.These rats are divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 0.70g/kg dosed administration group; This Chinese medicinal capsule 0.70,0.35, three dosed administration groups of 0.18g/kg.Be administered once every day, successive administration 7 days.After the last administration 1 hour, open former otch, cotton balls is taken out together with connective tissue on every side, reject fatty tissue, put 70 ℃ of oven dry in the baking oven, weigh.With claim weight deduct the former weight of cotton balls and promptly get granuloma weight.The results are shown in Table 3.
By table 3 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule cause the swelling of rat granulation that the obvious suppression effect is arranged to cotton balls, and present certain dose-effect relationship.
1.4, xylol causes the inhibitory action of Mice Auricle inflammation swelling:
Get 60 mices, be divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 1.00g/kg dosed administration group; This Chinese medicinal capsule 1.00,0.50, three dosed administration groups of 0.25g/kg.Be administered once every day, successive administration 5 days.After the last administration after 1 hour, each is organized all animals dimethylbenzene 0.03ml is applied to the Mice Auricle auris dextra causes swollenly, left ear is done normal control.After 2 hours, put to death animal, draw materials in the punching of auricle same area with the 9mm card punch, weigh respectively, heavily deducting left ear recast with auris dextra is the swelling level index.The results are shown in Table 4.
By table 4 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule 1.00,0.50g/kg xylol cause the swelling of Mice Auricle inflammation the obvious suppression effect.
1.5, to the outgrowth influence of mice filter paper granuloma:
Get 60 mices, be divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 1.00g/kg dosed administration group; This Chinese medicinal capsule 1.00,0.50, three dosed administration groups of 0.25g/kg.The mouse web portion routine disinfection is done a little otch that is about 0.3cm in the abdominal part median line, implants the 4mg filter paper of sterilizing subcutaneous, sew up the incision, routine disinfection, postoperative began administration the same day, and be administered once every day, successive administration 8 days, hara kiri skin was peeled off and is taken out filter paper and granuloma with mice execution in the 9th day, place 80 ℃ of oven dryings to take out after one hour and weigh, the weight that deducts former filter paper is granulomatous weight.The results are shown in Table 5.
By table 5 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule 1.00,0.50g/kg cause the mice granulation hyperplasia that the obvious suppression effect is arranged to the mice filter paper.
1.6, to the influence of mouse peritoneal capillary permeability:
Get 60 mices, be divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 1.00g/kg dosed administration group; This Chinese medicinal capsule 1.00,0.50, three dosed administration groups of 0.25g/kg.Be administered once every day, successive administration 5 days.After the last administration 1 hour in mouse tail vein injection 1% Yi Wensilan 0.1ml/10g body weight, lumbar injection 0.7% acetic acid 0.1ml/10g body weight immediately, put to death mice after 20 minutes, with 2ml normal saline flushing abdominal cavity, extract 1.6ml peritoneal irrigation liquid and add normal saline 5ml so far, centrifugal, with 752 type spectrophotometers in 590nm place colorimetric.The results are shown in Table 6.
By table 6 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule 1.00,0.50g/kg Dichlorodiphenyl Acetate cause the mouse peritoneal capillary permeability to strengthen the obvious suppression effect.
2, analgesic activity:
2.1, to the influence of mice hot plate zest pain:
Screen 55 of qualified female mices with hot plate dolorimeter 1 (MGJ-8402 type, 55 ± 0.5 ℃), be divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 1.00g/kg dosed administration group; This Chinese medicinal capsule 1.00,0.50, three dosed administration groups of 0.25g/kg.Be administered once every day, successive administration 5 days.Measure the mice pain threshold in 1,2,3,4,5 hour after the last administration, the results are shown in Table 7.
By table 7 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule cause that to hot plate mice pain has significant analgesia role, and sustainable 5 hours of action time of this Chinese medicinal capsule 1.00g/kg dosed administration group.
2.2, the influence of Dichlorodiphenyl Acetate induced mice pain:
Get 60 mices, be divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 1.00g/kg dosed administration group; This Chinese medicinal capsule 1.00,0.50, three dosed administration groups of 0.25g/kg.Be administered once every day, successive administration 5 days.The interior mouse writhing reaction times of 10min behind each Mus ip0.7% acetic acid 10ml/kg observation in 0.5 hour and the record 5min after the last administration.The results are shown in Table 8.
By table 8 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule 1.00,0.50g/kg group Dichlorodiphenyl Acetate causes the mouse writhing reaction times to increase that the obvious suppression effect is arranged.
3, function of promoting blood circulation to disperse blood clots
3.1, to the influence of rat thrombus in vivo:
Get 50 of rats, be divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 0.70g/kg dosed administration group; This Chinese medicinal capsule 0.70,0.35, three dosed administration groups of 0.18g/kg.Be administered once every day, successive administration 5 days.Back of the body position was fixing, separated right carotid in animal lumbar injection 300mg/kg chloral hydrate anesthesia in 1 hour after the last administration, form analyzer with experimental thrombus in vivo, far-end is put thermal detector, behind 2.0mA galvanic stimulation 3min, write down its duration of congestion, i.e. thrombus formation time.The results are shown in Table 9.
By table 9 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule 0.70,0.35g/kg group are formed with the obvious suppression effect to the rat thrombus in vivo.
3.2, to the thrombotic influence of blood stasis model rats in vitro:
Get 48 of rats, be divided into 6 groups at random.The blank group; The blood stasis model group; KANGFUYAN JIAONANG 0.70g/kg dosed administration group; This Chinese medicinal capsule 0.70,0.35, three dosed administration groups of 0.18g/kg.Be administered once every day, successive administration 5 days, in administration the 2nd, the 3rd day except that the blank group all the other each groups subcutaneous injection 0.1% epinephrines (Adr) 0.1ml/ are only respectively
[7], respectively rat is placed 1.5 ℃ of frozen water 5min that swims behind the 30min, only injecting Adr on the 4th day does not carry out ice bath, prepares blood stasis model with this.The blood sampling of abdomen cardinal vein was observed external thrombus and is formed situation on extracorporeal thrombosis forming device, be index with thrombosis length, weight in wet base, dry weight in each treated animal lumbar injection 300mg/kg chloral hydrate anesthesia in 1 hour after the last administration.The results are shown in Table 10.
By table 10 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule 0.70, two dosed administration groups of 0.35g/kg can obviously suppress rats in vitro thrombosis, thrombosis length and thrombus weight.
3.3, to the influence of clotting time of mice:
Get 60 mices, be divided into 5 groups at random.The blank group; KANGFUYAN JIAONANG 1.00g/kg dosed administration group; This Chinese medicinal capsule 1.00,0.50, three dosed administration groups of 0.25g/kg.Be administered once every day, successive administration 5 days.After the last administration 1 hour by mice socket of the eye venous blood collection, survey clotting time with slide method.The results are shown in Table 11.
By table 11 result as seen, KANGFUYAN JIAONANG and this Chinese medicinal capsule 1.00,0.50g/kg group can obviously prolong the clotting time of mice.
Pharmacodynamic experiment is the result show, the rat paw edema that this Chinese medicinal capsule on Carrageenan causes, the swelling of mice caused by dimethylbenzene xylene auricle inflammation have the obvious suppression effect, cause swelling of rat granulation and filter paper to cause the mice granulation hyperplasia that the obvious suppression effect is arranged to swelling, the cotton balls of rat uterus inflammation; The mouse peritoneal capillary permeability that Dichlorodiphenyl Acetate causes strengthens obvious inhibitory action; This Chinese medicinal capsule causes that to hot plate the mouse writhing increased frequency that mice pain and acetic acid cause has the obvious suppression effect.This Chinese medicinal capsule can obviously suppress rat vivo and vitro thrombosis, prolongs clotting time.
This Chinese medicinal capsule of table 2. is to the influence of rat uterus inflammation
This Chinese medicinal capsule of table 3. is to the granulomatous influence of rat
This Chinese medicinal capsule of table 4. is to the influence of mice dimethylbenzene dropsy of ear
This Chinese medicinal capsule of table 5. is to the granulomatous influence of mice
This Chinese medicinal capsule of table 6. is to the influence of mouse peritoneal capillary permeability
This Chinese medicinal capsule of table 8. Dichlorodiphenyl Acetate brings out the influence (X ± s) of mouse writhing reaction
This Chinese medicinal capsule of table 9. is to the influence of rat thrombus in vivo
This Chinese medicinal capsule of table 11. is to the influence of clotting time of mice
Claims (7)
1. Chinese medicine for the treatment of chronic pelvic inflammatory disease is characterized in that: the oral formulations that this Chinese medicine is obtained by following parts by weight of Chinese traditional medicine material compositions processing:
2. Chinese medicine according to claim 1 is characterized in that:
3. Chinese medicine according to claim 1 and 2 is characterized in that: also contain Rhizoma Curcumae 60-100 part, Rhizoma Corydalis 60-100 part in the Chinese crude drug compositions.
4. Chinese medicine according to claim 3 is characterized in that: 80 parts of Rhizoma Curcumae, 80 parts of Rhizoma Corydalis.
5. according to claim 1 or 2 or 4 described Chinese medicines, it is characterized in that: described oral formulations is selected from capsule, granule, ordinary tablet or slow releasing tablet.
6. Chinese medicine according to claim 5 is characterized in that: described oral formulations is a capsule.
7. preparation method of Chinese medicine for the treatment of chronic pelvic inflammatory disease is characterized in that:
(1) Radix Paeoniae Rubra, Radix Sophorae Flavescentis, the Radix Salviae Miltiorrhizae of getting proportional quantity mixes, and adds at least 5 times of amount 75-85% alcohol reflux at least twice, is no less than 1 hour at every turn, isolated by filtration obtains filtrate and filtering residue, merging filtrate, concentrating under reduced pressure reclaims ethanol, and the thick paste I that is concentrated into relative density 1.25-1.40 is standby;
(2) above-mentioned filtering residue mixes with Rhizoma Smilacis Glabrae, Herba Taraxaci, Rhizoma Fagopyri Dibotryis, Rhizoma Curcumae, Rhizoma Cyperi, the Radix Achyranthis Bidentatae of proportional quantity, adds the water reflux, extract, of at least 8 times of amounts or decocts at least twice, is no less than 1 hour at every turn, and isolated by filtration obtains filtrate and filtering residue;
(3) filtrate that obtains of combining step (2) is evaporated to the clear paste of relative density 1.05-1.20, adds ethanol, make determining alcohol 55-65%, leave standstill after fully stirring, separate to precipitating complete after-filtration, filtrate decompression concentrates and reclaims ethanol, is concentrated into the thick paste II for future of relative density 1.25-1.40;
(4) merge thick paste I and thick paste II and mix with the Rhizoma Corydalis fine powder and to be aided with the adjuvant that pharmaceutically allows and to process oral formulations with known method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110226694 CN102274433A (en) | 2011-08-09 | 2011-08-09 | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110226694 CN102274433A (en) | 2011-08-09 | 2011-08-09 | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102274433A true CN102274433A (en) | 2011-12-14 |
Family
ID=45100376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110226694 Pending CN102274433A (en) | 2011-08-09 | 2011-08-09 | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102274433A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127427A (en) * | 2013-03-09 | 2013-06-05 | 张翠红 | Chinese medicinal composition for treating chronic pelvic inflammation |
| CN103157048A (en) * | 2011-12-15 | 2013-06-19 | 深圳太太药业有限公司 | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof |
| CN103721131A (en) * | 2013-12-30 | 2014-04-16 | 青岛恒波仪器有限公司 | Traditional Chinese medicinal suppository for treating female chronic pelvic inflammation and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601832A (en) * | 2008-06-12 | 2009-12-16 | 张晓芳 | A kind of medicine for the treatment of chronic pelvic inflammatory disease and preparation method thereof |
-
2011
- 2011-08-09 CN CN 201110226694 patent/CN102274433A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601832A (en) * | 2008-06-12 | 2009-12-16 | 张晓芳 | A kind of medicine for the treatment of chronic pelvic inflammatory disease and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103157048A (en) * | 2011-12-15 | 2013-06-19 | 深圳太太药业有限公司 | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof |
| CN103157048B (en) * | 2011-12-15 | 2014-07-23 | 深圳太太药业有限公司 | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof |
| CN103127427A (en) * | 2013-03-09 | 2013-06-05 | 张翠红 | Chinese medicinal composition for treating chronic pelvic inflammation |
| CN103721131A (en) * | 2013-12-30 | 2014-04-16 | 青岛恒波仪器有限公司 | Traditional Chinese medicinal suppository for treating female chronic pelvic inflammation and preparation method thereof |
| CN103721131B (en) * | 2013-12-30 | 2016-06-01 | 赵玉妹 | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
| CN102038975A (en) | Chinese medicinal herbal plant liquid cotton gauze sanitary towel | |
| CN103638366B (en) | A kind of Chinese medicine for vaginal discharge diseases of women and preparation method thereof | |
| CN102743662B (en) | Zhuang medicine preparation for treating gynecological inflammation and preparation method thereof | |
| CN100372559C (en) | Traditional Chinese emdicine compounding prepns. for treating fracture | |
| CN102274433A (en) | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN106492069B (en) | Chinese medicine composition and the application for preventing and treating chronic pelvic inflammatory disease | |
| CN104906465A (en) | Traditional Chinese medicine blood-stasis dispersing composition for treating woman chronic pelvic inflammation and preparation method thereof | |
| CN102357219A (en) | Traditional Chinese medicament for curing gynaecological damp and hot morbid leucorrhea and preparation method thereof | |
| CN102302505B (en) | Medicinal composition for treating pelvic inflammatory disease and application thereof | |
| CN104814998A (en) | Traditional Chinese medicine composition for treating gynecologic inflammation | |
| CN106214740A (en) | A kind of Chinese medicine composition and its production and use | |
| CN104324317B (en) | A kind of Chinese medicine composition and medical usage for treating fibroid | |
| CN103316166B (en) | Tibetan medicine for treating hemorrhoids and preparation method thereof | |
| CN102579528B (en) | Medicine composition for preventing and curing prostatic diseases | |
| CN102068616A (en) | Medicament for treating gynecological diseases and preparation method | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN103623122B (en) | A kind of Chinese medicine for hemorrhoid and preparation method thereof | |
| CN103656084B (en) | It is a kind of to treat pharmaceutical composition of chronic pelvic inflammatory disease and preparation method thereof | |
| CN107050359B (en) | Zhuang medicine preparation for treating sequelae of chronic pelvic inflammatory disease and preparation method thereof | |
| CN105055831A (en) | Traditional Chinese medicine for treating leukorrhagia of women and preparation method thereof | |
| CN1970020B (en) | A pharmaceutical composition, preparation process and application thereof | |
| CN104367946A (en) | Traditional Chinese medicine suppository for treating chronic endometritis and preparation method thereof | |
| CN105456808B (en) | Gynaecopathia external prescription | |
| CN104258175A (en) | Traditional Chinese medicine for treating kidney calculi and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111214 |